[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qi deng\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":130},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,65,84,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100639937","phase-1-cd20-monoclonal-antibody-combined-with-btk-inhibitor-for-the-treatment-of-refractory-immune-related-cytopenia-100639937",false,"NCT07574073","CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia","Clinical Study on the Treatment of Refractory Immune-related Cytopenia With CD20 Monoclonal Antibody Combined With BTK Inhibitor (BTKi)","Inclusion Criteria:\n\n* Diagnosed with refractory immune-related cytopenia, including immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA);\n* Age ranging from 18 to 80 years old (inclusive of 18 and 80);\n* Expected survival time \\> 12 months;\n* Good function of major organs:\n\n  1. liver function: ALT\u002FAST \\\u003C 3 times the upper limit of normal;\n  2. kidney function: creatinine \\\u003C 100 μmol\u002FL;\n  3. lung function: indoor oxygen saturation ≥ 95%;\n  4. heart function: left ventricular ejection fraction (LVEF) ≥ 50%;\n* Peripheral superficial venous blood flow is unobstructed, capable of meeting the requirements for intravenous infusion;\n* Karnofsky score ≥ 60, ECOG ≤ 2 points.\n\nExclusion Criteria:\n\n* Women who are pregnant (with positive urine\u002Fblood pregnancy test results) or breastfeeding;\n* Those who have severe underlying heart diseases when participating in this study, including:\n\n  1. clinically significant atrial fibrillation (AF),\n  2. cardiac conduction block,\n  3. myocardial infarction (within 1 year),\n  4. congestive heart failure (CHF);\n  5. cardiac echocardiography LVEF \\\u003C 50%;\n  6. New York Heart Association (NYHA) cardiac function classification of III-IV grade;\n* Those with active bleeding or bleeding tendencies, and those who need to take anticoagulant drugs;\n* Those with organ dysfunction or uncontrollable coexisting diseases;\n* History of malignant tumors;\n* Those with active chronic hepatitis B or active hepatitis C;\n* Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome;\n* Those with uncontrollable infectious diseases;\n* As determined by the investigator, other unsuitable conditions exist.","ALL","18 Years","80 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study aims to utilize anti-CD20 monoclonal antibodies to eliminate peripheral B cells and reduce the mechanism of autoantibody production, as well as combine the mechanism of BTK inhibitors (BTKi) blocking the B cell receptor signaling pathway and inhibiting B cell activation and proliferation, for the treatment of refractory immune-related cytopenia. In this study, it includes the salvage treatment of immune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA), expecting to achieve a synergistic and enhancing effect. This study aims to select Zuberitamab, a human-mouse chimeric anti-CD20 monoclonal antibody, and the BTKi Orelabrutinib as combination therapy options. The clinical efficacy of the Zuberitamab-Orelabrutinib combination therapy (overall response rate, duration of sustained remission) will be evaluated, along with its safety profile (including infections, bleeding, cardiac toxicity), to provide a theoretical basis for their combined use in treating refractory immune-related thrombocytopenia (ITP and AIHA).",[27,28,29,30],"Anti-CD20 Monoclonal Antibody","BTK Inhibitors","Immune Thrombocytopenia (ITP)","Autoimmune Hemolytic Anemia (AIHA)","NOT_YET_RECRUITING","2026-05-19",{"date":34,"type":35},"2026-05-22","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2028-05-31",{"name":41,"class":42},"Qi deng","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":64,"locationsCount":4},"100634363","phase-1-functionally-optimized-cd33-car-t-cell-therapy-targeting-recurrentrefractory-acute-myeloid-leukemia-100634363","NCT07538713","Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent\u002FRefractory Acute Myeloid Leukemia","Clinical Study on the Efficacy and Safety of Functionally Optimized CD33 CAR-T Cells (FO33 CAR-T) Therapy Targeting CD33-Positive Recurrent\u002FRefractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n* Subjects diagnosed with refractory\u002Frecurrent acute myeloid leukemia (excluding M3) who meet any of the following criteria:\n\n  1. Relapse: Recurrence of leukemia cells in peripheral blood or ≥5% blast cells in bone marrow after complete remission (CR) of AML (excluding other causes such as bone marrow regeneration following consolidation chemotherapy), or extramedullary leukemia infiltration.\n  2. Refractory: First-time cases unresponsive to two cycles of standard therapy; relapse within 12 months after consolidation therapy following CR; relapse after 12 months without response to conventional chemotherapy; two or more relapses; persistent extramedullary leukemia.\n* During enrollment screening, bone marrow flow cytometry must demonstrate a CD33+ expression rate of ≥80% in leukemia cells and\u002For pathological immunohistochemical confirmation of CD33+ extramedullary lesions.\n* Estimated survival duration exceeding 3 months as of the date of informed consent signing.\n* Participants with Eastern Cooperative Oncology Group (ECOG) physical status scores ranging from 0 to 2.\n* Age range of 14 years ≤ ≤ 75 years, inclusive, with no gender restriction.\n* Hemoglobin (HGB) level ≥70 g\u002FL with transfusion capability.\n* Liver\u002Fkidney function and cardiopulmonary function meeting the following criteria:\n\n  1. Creatinine ≤1.5×ULN;\n  2. Left ventricular ejection fraction ≥50%;\n  3. Blood oxygen saturation\\>90%;\n  4. Total bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN.\n* Acceptance of autologous CART cells with peripheral blood tumor burden ≤ 30%;\n* The subject or guardian understands and signs the informed consent form.\n\nExclusion Criteria:\n\n* Presence of one of the following cardiac criteria:\n\n  1. Atrial fibrillation;\n  2. Myocardial infarction (MI) within the past 12 months;\n  3. Prolonged QT syndrome or secondary QT prolongation as determined by the investigator;\n  4. Echocardiographic left ventricular systolic fraction (LVSF) \\\u003C30% or left ventricular ejection fraction (LVEF) \\\u003C50%;\n  5. Clinically significant pericardial effusion; New York Heart Association (NYHA) class III or IV heart failure (confirmed by echocardiography within 12 months after treatment).\n* Active graft-versus-host disease (GVHD).\n* History of severe pulmonary dysfunction.\n* Concurrent other progressive malignancies.\n* Concurrent severe or persistent infections that cannot be effectively controlled.\n* Concurrent severe autoimmune diseases or congenital immunodeficiency.\n* Active hepatitis (HBV-DNA ≥ 500 IU\u002Fml with abnormal liver function or HCV antibody \\[HCV-Ab\\] positivity, HCV-RNA exceeding the detection limit of analytical methods with abnormal liver function).\n* Human immunodeficiency virus (HIV) infection or syphilis infection.\n* History of severe allergic reactions to biological products (including antibiotics).\n* Presence of central nervous system disorders such as uncontrolled epilepsy, cerebrovascular ischemia\u002Fhemorrhage, dementia, or cerebellar diseases.\n* Female patients in pregnancy or lactation, or planning pregnancy within 12 months.\n* Situations where investigators consider may increase subject risk or interfere with trial outcomes.","14 Years","75 Years",{"count":53,"type":21},18,[24],"Relapsed\u002Frefractory acute myeloid leukemia (R\u002FR AML) currently lacks effective CAR-T therapeutic agents due to the absence of tumor-specific target antigens. Most AML-associated antigens are expressed on normal hematopoietic stem\u002Fprogenitor cells (HSPCs) and healthy tissues, increasing the risk of on-target off-tumor toxicity and non-neoplastic toxicity. CD33 is present on leukemic cells in over 80% of AML patients. Compared with CLL-1, CD123 and other targets, CD33 exhibits higher expression across diverse AML subtypes, reducing the risk of treatment failure and relapse caused by antigen escape and thus serving as an ideal therapeutic target for AML. However, conventional CD33-targeted CAR-T cells demonstrate suboptimal efficacy in clinical trials, accompanied by significant toxicity and inadequate in vivo expansion. To further investigate the safety and efficacy of CAR-T therapy for AML, our center has initiated a clinical trial of functionally optimized CD33 CAR-T (FO33 CAR-T) cells for R\u002FR AML. We constructed a lentiviral CAR vector containing the CD33-targeting scFv, 4-1BB, and CD3ζ, followed by insertion of adjuvant molecule X. FO33 CAR-T cells showed superior cytotoxicity against AML cell lines and enhanced biological activity compared with conventional CD33 CAR-T cells, and exerted safe and effective antitumor effects in preclinical models. This single-center, open-label, prospective clinical trial aims to evaluate the safety and efficacy of FO33 CAR-T cells in patients with R\u002FR AML, as well as to characterize the pharmacokinetic and pharmacodynamic (PK\u002FPD) profiles of this therapy.",[57,58],"CAR T Cell Therapy","CD33 Positive Acute Myelogenous Leukemia","2026-04-19",{"date":61,"type":35},"2026-04-23",{"date":37,"type":21},{"date":39,"type":21},{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":83,"locationsCount":4},"100622408","phase-1-cd19baff-r-in-vivo-car-t-cell-therapy-targeting-relapsedrefractory-b-cell-acute-leukemiamalignant-lymphoma-100622408","NCT07383233","CD19\u002FBAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed\u002FRefractory B Cell Acute Leukemia\u002FMalignant Lymphoma","Clinical Study on the Efficacy and Safety of CD19\u002FBAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed\u002FRefractory B Cell Acute Leukemia\u002FMalignant Lymphoma","Inclusion Criteria:\n\nSubjects must meet all of the following criteria：\n\n* The diagnosis was confirmed as B-cell acute leukemia\u002Fmalignant lymphoma. Requirements for prior treatment: Patients with B-cell acute leukemia\u002Fmalignant lymphoma who failed to achieve PR after first-line therapy or experienced relapse within 12 months after first-line therapy; or those with relapsed\u002Frefractory disease after second-line therapy (a standardized chemotherapy regimen plus salvage chemotherapy). During screening, the patient was in a state of disease recurrence or refractory condition: Acute B-cell leukemia: a) Relapse definition: The presence of blast cells (proportion\\>5%) in peripheral blood or bone marrow after achieving complete remission with a standardized treatment regimen (including hematopoietic stem cell transplantation), or the development of extramedullary disease; b) Refractory definition: Failure to achieve complete remission after at least two courses of standardized induction therapy. B-cell lymphoma: a) Definition of relapse: PD after achieving remission (including partial response (PR) or complete response (CR)) following adequate treatment; b) Definition of refractory: i. No response to the last treatment: PD during\u002Fafter the last treatment or SD with a duration of less than 6 months; ii. Relapse or progression after ASCT, including: relapse or PD within 12 months after ASCT, and no response to the last treatment (SD or PD) if salvage therapy is administered.\n* The subject's predicted survival time is not less than three months.\n* Tumor cells confirmed to be CD19\u002FBAFFR positive by Flow Cytometry (FCM) or Immunohistochemistry.\n* Patients with relapsed\u002Frefractory B-cell acute lymphoblastic leukemia (B-ALL) and relapsed\u002Frefractory B-cell lymphoma (B-LY) who have at least one evaluable lesion.\n* Age 14-75 years (inclusive), both genders eligible.\n* ECOG performance status ≤ 3.\n* HGB≥70g\u002FL(transfusion permitted).\n* The functions of vital organs need to meet the following conditions: ①Creatinine ≤ 2.5 × ULN or Cockcroft-Gault creatinine clearance \\> 50 ml\u002Fmin (excluding decreased serum creatinine clearance due to lymphoma mass compression), Combination with hemodialysis treatment is permitted. ②LVEF≥50%,② Oxygen saturation ≥90%,③ SCr≤2.5ULN,④ALT and AST≤3ULN,TBil≤2ULN. In the investigator's judgment, if organ dysfunction is associated with the current disease, the enrollment decision will be made by the investigator.\n* Subjects intending to conceive must agree to use contraception prior to study enrollment and for six months post-study. In the event of pregnancy or suspected pregnancy, they should promptly notify the investigator.\n* The subject or guardian understands and signs the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\nAny of the following conditions will not be eligible for enrolment:\n\n* Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 50%.\n* History of severe pulmonary function impairment.\n* Concurrent other progressive malignant tumors.\n* Concurrent severe infection that cannot be effectively controlled.\n* Concurrent severe autoimmune disease or congenital immunodeficiency.\n* Active hepatitis (hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) positive with HBV DNA copy number greater than the upper limit of normal at the study center; Anti-HCV positive with HCV-RNA copy number greater than the upper limit of normal at the study center).\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.\n* History of severe allergy to biological products (including antibiotics).\n* Received inactivated vaccines such as influenza vaccine, COVID-19 vaccine within 4 weeks prior to screening, or received live attenuated vaccines (such as measles, varicella vaccines) within 8 weeks.\n* Patients with other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of study participation or interfere with study results, and patients considered unsuitable for this study by the investigator.",{"count":53,"type":21},[24],"The currently CAR-T cell therapy in clinical practice largely depends on the expansion of CAR-T cells in vivo. However, the in vitro preparation process of CAR-T cells is complex and costly. In vivo CAR-T cell therapy eliminates the need for ex vivo preparation, significantly reducing treatment costs and procedural complexity. It enables immediate use, thereby improving patient accessibility. CD19 is stably overexpressed in more than 90% of B-cell malignancies. BAFF plays a core regulatory role in the survival, maturation, and homeostasis maintenance of B cells. BAFF-R is selectively expressed on the surface of mature B cell subsets and most B-cell malignancies. Currently, BAFF-R-based CAR-T therapy is in preclinical and early clinical research stages, demonstrating promising therapeutic potential, particularly offering a novel treatment option for patients with CD19-negative or drug-resistant B-cell tumors. The use of CD19\u002FBAFF-R in vivo CAR-T cells as a new anti-tumor therapy may provide a new research direction for the treatment of relapsed\u002Frefractory B-cell acute leukemia\u002Fmalignant lymphoma.",[76,57,77],"Lymphoma","Acute Leukemia","2026-01-28",{"date":80,"type":35},"2026-02-03",{"date":37,"type":21},{"date":39,"type":21},{"name":41,"class":42},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100621010","early-phase-1-safety-and-efficacy-of-gprc5d-car-t-cell-therapy-in-relapsedrefractory-plasma-cell-disorders-100621010","NCT07365059","Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed\u002FRefractory Plasma Cell Disorders","Clinical Study on Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed\u002FRefractory Plasma Cell Disorders","Inclusion Criteria:\n\nSubjects must meet all of the following criteria：\n\n* According to the World Health Organization (WHO) Classification of Haematopoietic and Lymphoid Tissue Tumours (2022), patients with relapsed\u002Frefractory plasma cell disorders that have received adequate treatment and lack effective therapeutic options, including: multiple myeloma, plasma cell leukemia, extramedullary plasmacytoma, solitary plasmacytoma, or primary amyloidosis.i) Relapsed: Disease progression occurs after one or more prior treatments, requiring salvage therapy, and does not meet the criteria for refractory disease.ii) Refractory: No response to initial treatment regimen or salvage therapy, or disease progression within 60 days after treatment. No response is defined as failure to achieve minimal response (MR) or disease progression during treatment.\n* The subject's predicted survival time is not less than three months.\n* Tumor cells confirmed to be GPRC5D positive by Flow Cytometry (FCM) or Immunohistochemistry.\n* The subject failed autologous and allogeneic hematopoietic stem cell transplantation.\n* Age 14-75 years (inclusive), both genders eligible.\n* ECOG performance status ≤ 2.\n* HGB≥70g\u002FL(transfusion permitted).\n* The functions of vital organs need to meet the following conditions: ①Creatinine ≤ 2.5 × ULN or Cockcroft-Gault creatinine clearance \\> 50 ml\u002Fmin (excluding decreased serum creatinine clearance due to lymphoma mass compression), Combination with hemodialysis treatment is permitted. ②LVEF≥50%,② Oxygen saturation ≥90%,③ SCr≤2.5ULN,④ALT and AST≤3ULN,TBil≤2ULN. In the investigator's judgment, if organ dysfunction is associated with the current disease, the enrollment decision will be made by the investigator.\n* Subjects intending to conceive must agree to use contraception prior to study enrollment and for six months post-study. In the event of pregnancy or suspected pregnancy, they should promptly notify the investigator.\n* The subject or guardian understands and signs the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\nAny of the following conditions will not be eligible for enrolment:\n\n* Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 50%.\n* History of severe pulmonary function impairment.\n* Concurrent other progressive malignant tumors.\n* Concurrent severe infection that cannot be effectively controlled.\n* Concurrent severe autoimmune disease or congenital immunodeficiency.\n* Active hepatitis (hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) positive with HBV DNA copy number greater than the upper limit of normal at the study center; Anti-HCV positive with HCV-RNA copy number greater than the upper limit of normal at the study center).\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.\n* History of severe allergy to biological products (including antibiotics).\n* Received inactivated vaccines such as influenza vaccine, COVID-19 vaccine within 4 weeks prior to screening, or received live attenuated vaccines (such as measles, varicella vaccines) within 8 weeks.\n* Allogeneic hematopoietic stem cell transplant patients with persistent acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents.\n* Patients with other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of study participation or interfere with study results, and patients considered unsuitable for this study by the investigator.",{"count":53,"type":21},[93],"EARLY_PHASE1","This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed\u002Frefractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects relevant data on treatment efficacy, evaluates the safety and efficacy of CAR-T cells, and simultaneously investigates the cellular kinetic characteristics of CAR-T cells.",[96],"Plasma Cell Dyscrasias","2026-01-15",{"date":99,"type":35},"2026-01-26",{"date":101,"type":21},"2026-01-25",{"date":103,"type":21},"2029-03-01",{"name":41,"class":42},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100593625","cd7-car-t-cell-therapy-targeting-cd7-positive-relapsedrefractory-t-cell-lymphomaacute-leukemia-100593625","NCT07008872","CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed\u002FRefractory T Cell Lymphoma\u002FAcute Leukemia","Clinical Study on the Efficacy and Safety of CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed\u002FRefractory T Cell Lymphoma\u002FAcute Leukemia","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1. Subjects diagnosed with relapsed\u002Frefractory lymphoma\u002Fleukemia:\n\n   1. Relapsed\u002Frefractory T-cell malignant lymphoma: patients who have not remission and recurrence after at least 2 courses of standardized second-line or above treatment (including hematopoietic stem cell transplantation).\n   2. Relapsed\u002Frefractory T-cell acute lymphocytic or myeloid leukemia meeting any of the following criteria:\n\n   i) Relapse: After achieving complete remission with a standard treatment regimen (including hematopoietic stem cell transplantation), blasts appear in peripheral blood or bone marrow (proportion\\>5%), or extramedullary diseases occur; ii) Refractory: No complete remission after at least two courses of standard induction therapy.\n2. Bone marrow flow cytometry detected tumor cells as CD7 and\u002For extramedullary lesions with a clear diagnosis of CD7 by pathological immunohistochemistry at the time of enrollment screening;\n3. If tumor cells are detected in peripheral blood during enrollment screening, flow cytometry must be used to detect that the immunophenotype of tumor cells on the surface of tumor cells is both negative for CD4 and CD8. If the immunophenotype on the surface of peripheral blood tumor cells is not CD4 and CD8 negative, the proportion of peripheral blood tumor cells must be ≤1%;\n4. Expected survival greater than 3 months from the date of signing the informed consent form;\n5. Subjects with a performance status of 0\\~2 in the Eastern Cooperative Oncology Group (ECOG) score;\n6. 14 years old≤ age ≤ 75 years old, male or female;\n7. HGB at least ≥70g\u002FL, blood transfusion is available;\n8. Liver and kidney function, heart and lung function meet the following requirements:\n\n   1. creatinine ≤1.5×ULN;\n   2. left ventricular ejection fraction ≥50%;\n   3. Oxygen saturation \\>90%;\n   4. Total bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN;\n9. Subject or guardian understands and signs the informed consent form.\n\nExclusion Criteria:\n\n1. One of the following cardiac criteria occurs: atrial fibrillation; Myocardial infarction within the past 12 months; Prolonged QT syndrome or secondary QT Extension, to be determined by the researcher. Echocardiography with LVSF\\\u003C30% or LVEF\\\u003C50%; Clinically significant pericardial effusion; Heart function Incomplete NYHA III or IV (confirmed by echocardiography within 12 months after treatment);\n2. Active GVHD;\n3. Have a history of severe pulmonary dysfunction;\n4. Merge other advanced malignant tumors;\n5. Combination of severe or persistent infections that cannot be effectively controlled;\n6. Combination of severe autoimmune diseases or congenital immunodeficiency;\n7. Active hepatitis (hepatitis B virus deoxyribonucleic acid \\[HBV-DNA ≥ 500 IU\u002Fml and abnormal liver function\\] or anti hepatitis C virus Positive for HCV Ab, HCV-RNA above the detection limit of the analytical method, and abnormal liver function;\n8. Human immunodeficiency virus (HIV) infection or syphilis infection;\n9. Have a history of severe allergies to biological products (including antibiotics);\n10. There are central nervous system disorders, such as uncontrolled epilepsy, cerebral ischemia\u002Fhemorrhage, dementia, cerebellar diseases, etc;\n11. Female patients who are pregnant or breastfeeding, or have a pregnancy plan within 12 months;\n12. The researcher believes that there may be situations that increase the risk to the subjects or interfere with the test results.",{"count":113,"type":21},40,[115],"NA","CD7 molecules are thought to be associated with disease aggressiveness, drug resistance, and poor prognosis. Intensive chemotherapy, immunotherapy, hematopoietic stem cell transplantation (HSCT) and other treatment regimens have achieved remarkable results in the treatment of hematologic malignant diseases. Nevertheless, patients with hematologic malignancies may still tolerate acquired therapy during the above treatments, and molecular targeted immunotherapy provides a safe, efficient and specific treatment for such patients The scheme has attracted more and more researchers' attention. The use of CD7 molecules as a new target for molecularly targeted anti-tumor therapy may provide a new research direction for the treatment of CD7 relapsed\u002Frefractory hematologic malignancies.",[118,119],"CD7+ Lymphoma","CD7+ Acute Leukemia",[121],"CD7 CART, AL, lymphoma","2025-06-04",{"date":124,"type":35},"2025-06-06",{"date":126,"type":21},"2025-06-01",{"date":128,"type":21},"2027-05-31",{"name":41,"class":42},""]